Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 1535 NEXT DPI versus HFA pMDI in moderate to severe asthma
2008-000401-11Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol, beclomethasone dipropionate and formoterol in asthma (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline in pre-dose morning FEV1 and Non-inferiority of NEXT DPI versus HFA pMDI. Started Aug 2008; status: completed.
02
Drugs
beclometasone dipropionate + formoterolbeclomethasone dipropionateformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2008-000401-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000401-11.